Amneal Pharmaceuticals, Inc. (AMRX) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Amneal Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$10.7 M, a 131% decline year-over-year.
  • Amneal Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was $159 M.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was $204 M.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$94.9 M, a 162% decline from 2021.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $153 M, a 67.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $159 M -$10.7 M -$45.2 M -131% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $204 M $14.2 M -$21.8 M -60.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $226 M $75.6 M +$31.3 M +70.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $195 M $80.1 M +$279 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$83.8 M $34.4 M +$11.1 M +47.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$94.9 M $36 M +$24.9 M +222% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$120 M $44.4 M +$15.8 M +55.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$136 M -$199 M -$266 M -396% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $130 M $23.3 M -$22.6 M -49.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $153 M $11.2 M -$9 M -44.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $162 M $28.5 M +$26.1 M +1071% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $136 M $67.1 M +$56.4 M +524% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $79.3 M $45.9 M -$11.9 M -20.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $91.2 M $20.2 M +$43.3 M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 $47.8 M $2.44 M +$115 M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$66.9 M $10.8 M +$29.7 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$96.5 M $57.8 M +$152 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$249 M -$23.1 M -$46.4 M -199% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$202 M -$112 M -$187 M -251% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$15.4 M -$18.9 M +$162 M +89.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$178 M -$94.4 M -$158 M -248% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$19.7 M $23.3 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $74.6 M -$4.2 M -5.33% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$181 M -$226 M -506% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $63.6 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q3 2017 $78.8 M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $44.6 M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.